How to Track Drug Patent Expiry Dates: Orange Book, Purple Book, and USPTO Explained

Patent expiry is not a single date. For a pharmaceutical product, loss of exclusivity depends on patents, FDA exclusivities, biologic reference status, litigation, market entry, and product-specific regulatory context. Data teams need to connect Orange Book, Purple Book, USPTO, and approval data before a patent cliff model is trustworthy.

Orange Book versus Purple Book

The Orange Book focuses on approved drug products, particularly small molecules and therapeutic equivalence. It includes patent listings, exclusivity entries, application numbers, product numbers, and active ingredient information. The Purple Book focuses on licensed biological products, reference products, biosimilars, and interchangeability status.

A lifecycle model needs both because IRA clocks, generic competition, and biosimilar competition follow different data structures.

Exclusivity codes matter

FDA exclusivity codes such as NCE, ODE, PED, NDF, GAIN, and others add protection that may be separate from patent expiry. A product can have several exclusivity entries with different scopes and end dates. Analysts should model exclusivity end dates alongside patent expiry rather than treating either as the whole answer.

Paragraph IV challenges

Paragraph IV certification is the mechanism by which generic applicants challenge Orange Book-listed patents. For competitive intelligence and loss-of-exclusivity tracking, Paragraph IV events indicate pressure before final generic entry. Patent, application, and product identifiers must be normalized to compare challenged patents with marketed products.

USPTO context adds depth

Orange Book patents are the FDA-listed subset. USPTO records add assignees, inventors, forward citations, publication numbers, CPC or IPC classes, government interest statements, and broader family context. That information is valuable for diligence and landscape work, but only if patent numbers are normalized into the same format.

SELECT
  drug.brand_name,
  ip.patent_number,
  ip.patent_expiry_date,
  ex.exclusivity_code,
  ex.exclusivity_expiry_date,
  uspto.forward_citation_count
FROM `tdd.ip.orange_book_patents` AS ip
JOIN `tdd.identity.drug_spine` AS drug USING (canonical_drug_id)
LEFT JOIN `tdd.ip.orange_book_exclusivity` AS ex USING (canonical_drug_id)
LEFT JOIN `tdd.ip.uspto_patents` AS uspto USING (patent_number);

Building a patent cliff model

Start with a canonical product identity, then layer application numbers, listed patents, exclusivities, biologic reference status, CMS spend, and competitor approvals. The final model should include earliest likely exposure, latest protection runway, generic or biosimilar evidence, and revenue at risk.

Insight: The highest-confidence LOE tracker is not an IP table alone. It is an integrated lifecycle table that joins FDA, USPTO, CMS, and identity data.

Related data products

• FDA Orange Book Patent Intelligence
• FDA Orange Book Exclusivity Intelligence
• USPTO Patent Intelligence